MTOR and neoplasm: Polymeric oligopeptide-modified pBAE nanoparticles, anisamide-functionalized for tumor selectivity, protect and deliver mTOR siRNA with serum stability, achieving specific NSCLC knockdown and antitumor efficacy in vitro and in vivo [26].